- Salix Pharmaceuticals introduces Rx topical foam to treat a form of inflammatory bowel disease
- FDA pushes back target date for review of Takeda drug in patients with ulcerative colitis
- Takeda starts phase-3 trials of vedolizumab
- FDA advisory committee recommends approval for Takeda's vedolizumab
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
PHILADELPHIA — The Food and Drug Administration has approved a drug made by Shire for treating ulcerative colitis, the British drug maker said Monday.
Shire announced the approval of Lialda (mesalamine) delayed-release tablets for the maintenance of remission in patients with the disease.
The drug was already approved for inducing remission in patients with ulcerative colitis, an inflammatory disease that affects the colon and causes chronic inflammation, sores and ulcers.